E. V. Yushkova
Research Subjects
E. V. Yushkova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Nadezhda A. Podoplelova
Center for Theoretical Problems of Physicochemical Pharmakology, 119991 Moscow, Russia
3 shared publications - Alexey V. Pshonkin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
1 shared publication - Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
1 shared publication - Anastasia Ignatova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
1 shared publication - D. V. Pavlenko
National Medical Research Center for Hematology
1 shared publication - Daria V. Fedorova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 258-270
Platelet hemostatic disorders: how to reach a diagnosis?
Introduction . Thrombocytopenia can be primary or secondary and warrants differential diagnosis of hereditary functional platelet defects. Aim : to present the difficulties of verifying the diagnosis in disorders of the platelet component of hemostasis. Main findings. A clinical case of a 28-year old female patient is presented. The patient presented with a mild mucocutaneous hemorrhagic syndrome and moderate thrombocytopenia of a familial nature. All available routine and alternative methods for investigating platelet disorders were performed. Whole genome sequencing proved to be a crucial diagnostic method. This genetic analysis, in comparison with morphological and functional studies, is a promising tool for the differential diagnosis of heterogeneous platelet disorders.
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 258-270
Open AccessPlatelet hemostatic disorders: how to reach a diagnosis?
Introduction . Thrombocytopenia can be primary or secondary and warrants differential diagnosis of hereditary functional platelet defects. Aim : to present the difficulties of verifying the diagnosis in disorders of the platelet component of hemostasis. Main findings. A clinical case of a 28-year old female patient is presented. The patient presented with a mild mucocutaneous hemorrhagic syndrome and moderate thrombocytopenia of a familial nature. All available routine and alternative methods for investigating platelet disorders were performed. Whole genome sequencing proved to be a crucial diagnostic method. This genetic analysis, in comparison with morphological and functional studies, is a promising tool for the differential diagnosis of heterogeneous platelet disorders.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 74-81
Essential thrombocythemia in childhood: features of platelet structure and function
Introduction. Essential thrombocythemia (ET) is an orphan myeloproliferative disease with excessive platelet production associated with an increased risk of thrombosis and bleeding. Currently, there is a limited number of studies on the state of platelet hemostasis in children with ET. Aim of this single-center prospective study was to characterize the morphological and functional properties of platelets in pediatric patients with ET. Materials and methods. The study included 30 patients (10 boys and 20 girls) aged 3–17 years with an established diagnosis of ET. The control group consisted of 45 healthy volunteers (22 boys and 23 girls) aged 4–18 years. Flow cytometry with strong and weak activation, aggregometry, and immunofluorescence microscopy of blood smears were used to analyze platelet function. Results. It was shown that platelets of patients with ET are characterized by a reduced size, while the number of platelet alpha and dense granules did not differ from the control group. Platelets of patients with ET showed moderate hyporeactivity in response to strong stimulation (by activation of glycoprotein IIbIIIa and secretion of dense granules). Platelet aggregation with collagen and adenosine diphosphate was also reduced in patients with ET, but these data did not correlate with the degree of platelet activation in flow cytometry. Conclusion. Thus, characteristic morphological and functional changes in platelets were revealed in children with ET compared with the control group.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 74-81
Open AccessEssential thrombocythemia in childhood: features of platelet structure and function
Introduction. Essential thrombocythemia (ET) is an orphan myeloproliferative disease with excessive platelet production associated with an increased risk of thrombosis and bleeding. Currently, there is a limited number of studies on the state of platelet hemostasis in children with ET. Aim of this single-center prospective study was to characterize the morphological and functional properties of platelets in pediatric patients with ET. Materials and methods. The study included 30 patients (10 boys and 20 girls) aged 3–17 years with an established diagnosis of ET. The control group consisted of 45 healthy volunteers (22 boys and 23 girls) aged 4–18 years. Flow cytometry with strong and weak activation, aggregometry, and immunofluorescence microscopy of blood smears were used to analyze platelet function. Results. It was shown that platelets of patients with ET are characterized by a reduced size, while the number of platelet alpha and dense granules did not differ from the control group. Platelets of patients with ET showed moderate hyporeactivity in response to strong stimulation (by activation of glycoprotein IIbIIIa and secretion of dense granules). Platelet aggregation with collagen and adenosine diphosphate was also reduced in patients with ET, but these data did not correlate with the degree of platelet activation in flow cytometry. Conclusion. Thus, characteristic morphological and functional changes in platelets were revealed in children with ET compared with the control group.
- Open Access
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 71-82
Comparison of imported and domestic antibody kits for immunofluorescence staining of platelets in blood smears
Introduction. The implementation of domestically produced antibodies for immunofluorescence staining of blood smears requires a thorough comparative analysis with foreign well-known analogues previously used in diagnosing inherited platelet disorders. Aim: to conduct a comparative analysis of domestic and foreign antibody kits for immunofluorescence analysis of blood smears used in the diagnosis of the two most common platelet disorders associated with membrane glycoprotein defects: Glanzmann thrombasthenia and Bernard–Soulier syndrome. Materials and methods. To compare the antibody effectiveness, immunofluorescence analysis of blood smears was carried out for 16 patients with Glanzmann thrombasthenia, 10 patients with Bernard–Soulier syndrome, and 25 healthy volunteers. Results. In this work, we carried out a qualitative comparison between domestic antibodies to platelet surface glycoproteins: IIbIIIa (CD41) and IbIX (CD42), as well as corresponding fluorescently labeled secondary antibodies and their foreign well-known analogues. It was shown that the domestic antibodies are not inferior to foreign well-known analogues. Clinical trials demonstrated that the expression of glycoprotein IbIX was reduced or completely absent in 10 out of 10 patients with confirmed Bernard–Soulier syndrome. Among 16 patients with confirmed Glanzmann thrombasthenia, only two (13%) did not show decreased or absent expression of glycoprotein IIbIIIa. The stability of blood smear samples stored under various conditions was also evaluated. Conclusion. A kit of antibodies against platelet glycoproteins (CD41, CD42) was validated. Immunofluorescence analysis of blood smears demonstrated 100% sensitivity for Bernard–Soulier syndrome and 87% sensitivity for Glanzmann thrombasthenia. The samples remained stable for up to 16 weeks at –20°C and at room temperature in vacuum packaging.
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 71-82
Open AccessComparison of imported and domestic antibody kits for immunofluorescence staining of platelets in blood smears
Introduction. The implementation of domestically produced antibodies for immunofluorescence staining of blood smears requires a thorough comparative analysis with foreign well-known analogues previously used in diagnosing inherited platelet disorders. Aim: to conduct a comparative analysis of domestic and foreign antibody kits for immunofluorescence analysis of blood smears used in the diagnosis of the two most common platelet disorders associated with membrane glycoprotein defects: Glanzmann thrombasthenia and Bernard–Soulier syndrome. Materials and methods. To compare the antibody effectiveness, immunofluorescence analysis of blood smears was carried out for 16 patients with Glanzmann thrombasthenia, 10 patients with Bernard–Soulier syndrome, and 25 healthy volunteers. Results. In this work, we carried out a qualitative comparison between domestic antibodies to platelet surface glycoproteins: IIbIIIa (CD41) and IbIX (CD42), as well as corresponding fluorescently labeled secondary antibodies and their foreign well-known analogues. It was shown that the domestic antibodies are not inferior to foreign well-known analogues. Clinical trials demonstrated that the expression of glycoprotein IbIX was reduced or completely absent in 10 out of 10 patients with confirmed Bernard–Soulier syndrome. Among 16 patients with confirmed Glanzmann thrombasthenia, only two (13%) did not show decreased or absent expression of glycoprotein IIbIIIa. The stability of blood smear samples stored under various conditions was also evaluated. Conclusion. A kit of antibodies against platelet glycoproteins (CD41, CD42) was validated. Immunofluorescence analysis of blood smears demonstrated 100% sensitivity for Bernard–Soulier syndrome and 87% sensitivity for Glanzmann thrombasthenia. The samples remained stable for up to 16 weeks at –20°C and at room temperature in vacuum packaging.